Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Express Scripts

Last Updated: December 3, 2022

Details for Patent: 8,420,629

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,420,629 protect, and when does it expire?

Patent 8,420,629 protects OLUMIANT and is included in one NDA.

This patent has fifty-six patent family members in forty-four countries.

Summary for Patent: 8,420,629
Title:Azetidine and cyclobutane derivatives as JAK inhibitors
Abstract: The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
Inventor(s): Rodgers; James D. (OveLandenberg, PA), Shepard; Stacey (Voorhees, NJ)
Assignee: Incyte Corporation (Wilmington, DE)
Application Number:13/315,750
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 8,420,629

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-002 Oct 8, 2019 RX Yes No See Plans and Pricing See Plans and Pricing TREATMENT OF RHEUMATOID ARTHRITIS See Plans and Pricing
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-001 May 31, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing TREATMENT OF RHEUMATOID ARTHRITIS See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,420,629

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 070828 See Plans and Pricing
Australia 2009223640 See Plans and Pricing
Brazil PI0909040 See Plans and Pricing
Canada 2718271 See Plans and Pricing
Chile 2009000576 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.